Multiple Sclerosis Drugs
Middle East · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Middle East Chronic Urticaria Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$188.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $140.2 Mn | — | — |
| 2025 (base) | $153.3 Mn | +$13.0 Mn | — |
| 2026 (forecast) | $167.5 Mn | +$14.3 Mn | +9.3% |
| 2027 (forecast) | $183.1 Mn | +$15.6 Mn | +19.5% |
| 2028 (forecast) | $200.1 Mn | +$17.0 Mn | +30.6% |
| 2029 (forecast) | $218.7 Mn | +$18.6 Mn | +42.7% |
| 2030 (forecast) | $239.1 Mn | +$20.3 Mn | +56% |
| 2031 (forecast) | $261.3 Mn | +$22.2 Mn | +70.5% |
| 2032 (forecast) | $285.6 Mn | +$24.3 Mn | +86.4% |
| 2033 (forecast) | $312.2 Mn | +$26.6 Mn | +103.7% |
| 2034 (forecast) | $341.2 Mn | +$29.0 Mn | +122.6% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $153.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $341.2 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, type and end user (see all) |
| Key players | Novartis AG, Sanofi, Regeneron Pharmaceuticals, Celldex Therapeutics, Roche (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Chronic urticaria treatments control long-lasting hives and itching that do not go away with standard antihistamines.
Key segments of the chronic Urticaria Treatment market include drug class (Antihistamines, Anti-IgE Biologics and BTK Inhibitors) and type (Chronic Spontaneous Urticaria and Chronic Inducible Urticaria).
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the chronic Urticaria Treatment market. Biosimilars are widening access.
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the chronic Urticaria Treatment market room to grow.
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the chronic Urticaria Treatment market.
The chronic Urticaria Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for chronic Urticaria Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.
What doctors and scientists are doing in Chronic Urticaria Treatment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 2 shared keywords
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Medical Devices · Middle East
Digital Health · Middle East
Medical Devices · Middle East
Healthcare Services · Middle East
OTC & Nutraceuticals · Middle East
OTC & Nutraceuticals · Middle East